Cargo Therapeutics(CRGX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 – 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 – - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - "We're ...